162 related articles for article (PubMed ID: 34665865)
1. All-trans retinoic acid plus low-dose rituximab vs low-dose rituximab in corticosteroid-resistant or relapsed ITP.
Wu YJ; Liu H; Zeng QZ; Liu Y; Wang JW; Wang WS; Jia-Feng ; Zhou HB; Huang QS; He Y; Fu HX; Zhu XL; Jiang Q; Jiang H; Chang YJ; Xu LP; Huang XJ; Zhang XH
Blood; 2022 Jan; 139(3):333-342. PubMed ID: 34665865
[TBL] [Abstract][Full Text] [Related]
2. Oral all-trans retinoic acid plus danazol versus danazol as second-line treatment in adults with primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial.
Feng FE; Feng R; Wang M; Zhang JM; Jiang H; Jiang Q; Lu J; Liu H; Peng J; Hou M; Shen JL; Wang JW; Xu LP; Liu KY; Huang XJ; Zhang XH
Lancet Haematol; 2017 Oct; 4(10):e487-e496. PubMed ID: 28917657
[TBL] [Abstract][Full Text] [Related]
3. A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP.
Zhou H; Xu M; Qin P; Zhang HY; Yuan CL; Zhao HG; Cui ZG; Meng YS; Wang L; Zhou F; Wang X; Li DQ; Bi KH; Zhu CS; Guo CS; Chu XX; Wu QC; Liu XG; Dong XY; Li J; Peng J; Hou M
Blood; 2015 Mar; 125(10):1541-7. PubMed ID: 25575541
[TBL] [Abstract][Full Text] [Related]
4. Single-dose versus low-dose rituximab in corticosteroid-resistant or relapsed ITP: A multicenter, randomized, controlled study.
Ni X; Li D; Yuan C; Yu Y; Wang H; Wang L; Yu T; Qin P; Peng J; Hou M; Shi Y; Hou Y
Am J Hematol; 2022 Apr; 97(4):440-447. PubMed ID: 35049070
[TBL] [Abstract][Full Text] [Related]
5. All-trans retinoic acid plus high-dose dexamethasone as first-line treatment for patients with newly diagnosed immune thrombocytopenia: a multicentre, open-label, randomised, controlled, phase 2 trial.
Huang QS; Liu Y; Wang JB; Peng J; Hou M; Liu H; Feng R; Wang JW; Xu LP; Wang Y; Huang XJ; Zhang XH
Lancet Haematol; 2021 Oct; 8(10):e688-e699. PubMed ID: 34560012
[TBL] [Abstract][Full Text] [Related]
6. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial.
Ghanima W; Khelif A; Waage A; Michel M; Tjønnfjord GE; Romdhan NB; Kahrs J; Darne B; Holme PA;
Lancet; 2015 Apr; 385(9978):1653-61. PubMed ID: 25662413
[TBL] [Abstract][Full Text] [Related]
7. Is splenectomy necessary for immune thrombocytopenic purpura? The role of rituximab in patients with corticosteroid resistance in a single-center experience.
Zhang C; Liu HF; Chen XH; Gao L; Gao L; Liu Y; Kong PY; Sun AH; Zhang X
Clin Ther; 2014 Mar; 36(3):385-8. PubMed ID: 24594069
[TBL] [Abstract][Full Text] [Related]
8. A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study).
Tran H; Brighton T; Grigg A; McRae S; Dixon J; Thurley D; Gandhi MK; Truman M; Marlton P; Catalano J
Br J Haematol; 2014 Oct; 167(2):243-51. PubMed ID: 25041261
[TBL] [Abstract][Full Text] [Related]
9. Anti-GPIb/IX autoantibodies are associated with poor response to dexamethasone combined with rituximab therapy in primary immune thrombocytopenia patients.
Ding B; Liu L; Li M; Song X; Zhang Y; Xia A; Liu J; Zhou H
Platelets; 2023 Dec; 34(1):2258988. PubMed ID: 37722393
[TBL] [Abstract][Full Text] [Related]
10. High-dose dexamethasone or all-trans-retinoic acid restores the balance of macrophages towards M2 in immune thrombocytopenia.
Feng Q; Xu M; Yu YY; Hou Y; Mi X; Sun YX; Ma S; Zuo XY; Shao LL; Hou M; Zhang XH; Peng J
J Thromb Haemost; 2017 Sep; 15(9):1845-1858. PubMed ID: 28682499
[TBL] [Abstract][Full Text] [Related]
11. Rituximab or cyclosporin in refractory immune thrombocytopenia secondary to connective tissue diseases: a real-world observational retrospective study.
Sun F; Chen J; Wu W; Geng S; Xu W; Sun S; Chen Z; Gu L; Wang X; Li T; Ye S
Clin Rheumatol; 2020 Oct; 39(10):3099-3104. PubMed ID: 32418039
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia.
Mahévas M; Ebbo M; Audia S; Bonnotte B; Schleinitz N; Durand JM; Chiche L; Khellaf M; Bierling P; Roudot-Thoraval F; Godeau B; Michel M
Am J Hematol; 2013 Oct; 88(10):858-61. PubMed ID: 23798363
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of rituximab in Japanese patients with relapsed chronic immune thrombocytopenia refractory to conventional therapy.
Miyakawa Y; Katsutani S; Yano T; Nomura S; Nishiwaki K; Tomiyama Y; Higashihara M; Shirasugi Y; Nishikawa M; Ozaki K; Abe T; Kikuchi K; Kanakura Y; Fujimura K; Ikeda Y; Okamoto S
Int J Hematol; 2015 Dec; 102(6):654-61. PubMed ID: 26466831
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Children with Persistent and Chronic Idiopathic Thrombocytopenic Purpura: 4 Infusions of Rituximab and Three 4-Day Cycles of Dexamethasone.
Oved JH; Lee CSY; Bussel JB
J Pediatr; 2017 Dec; 191():225-231. PubMed ID: 29173312
[TBL] [Abstract][Full Text] [Related]
15. Low-dose rituximab therapy in steroid-refractory thrombocytopenia due to systemic lupus erythematosus.
Ilizaliturri-Guerra O; Uriarte-Botello R; Pineda-Sic RÁ; Serna-Peña G; Garza-Elizondo MA; Galarza-Delgado DÁ; Leal-Bramasco AS; Elizondo-Solís CV; Santoyo-Fexas L; Villarreal-Alarcón MÁ
Rheumatol Int; 2020 Oct; 40(10):1717-1724. PubMed ID: 32797277
[TBL] [Abstract][Full Text] [Related]
16. Dexamethasone plus oseltamivir versus dexamethasone in treatment-naive primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial.
Sun L; Wang J; Shao L; Yuan C; Zhao H; Li D; Wang Z; Han P; Yu Y; Xu M; Zhao H; Qiu J; Zhou H; Liu X; Hou Y; Peng J; Hou M
Lancet Haematol; 2021 Apr; 8(4):e289-e298. PubMed ID: 33770484
[TBL] [Abstract][Full Text] [Related]
17. Preferential splenic CD8(+) T-cell activation in rituximab-nonresponder patients with immune thrombocytopenia.
Audia S; Samson M; Mahévas M; Ferrand C; Trad M; Ciudad M; Gautheron A; Seaphanh F; Leguy V; Berthier S; Salles B; Martin L; Lorcerie B; Ortega-Deballon P; Facy O; Caillot D; Soudry-Faure A; Michel M; Godeau B; Larmonier N; Saas P; Janikashvili N; Bonnotte B
Blood; 2013 Oct; 122(14):2477-86. PubMed ID: 23963041
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of treatments in newly diagnosed adult primary immune thrombocytopenia: A systematic review and network meta-analysis.
Wang Y; Sheng L; Han F; Guo Q; Zhang Z; Hou Y; Feng Q; Zhou H; Ji X; Peng J; Hou M; Xu M
EClinicalMedicine; 2023 Feb; 56():101777. PubMed ID: 36578882
[TBL] [Abstract][Full Text] [Related]
19. Immunologic effects of rituximab on the human spleen in immune thrombocytopenia.
Audia S; Samson M; Guy J; Janikashvili N; Fraszczak J; Trad M; Ciudad M; Leguy V; Berthier S; Petrella T; Aho-Glélé S; Martin L; Maynadié M; Lorcerie B; Rat P; Cheynel N; Katsanis E; Larmonier N; Bonnotte B
Blood; 2011 Oct; 118(16):4394-400. PubMed ID: 21876120
[TBL] [Abstract][Full Text] [Related]
20. Predictors of relapse and efficacy of rituximab in immune thrombotic thrombocytopenic purpura.
Sun L; Mack J; Li A; Ryu J; Upadhyay VA; Uhl L; Kaufman RM; Stowell CP; Dzik WS; Makar RS; Bendapudi PK
Blood Adv; 2019 May; 3(9):1512-1518. PubMed ID: 31076407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
